BBGBloomberg·3hBusiness
score-0.45
Roche Eyes Key New Drug to Reignite Growth as Vabysmo Recovery Continues
Original
Roche’s Second-Quarter Sales Held Back by Blockbuster Eye Drug
“Uses constraint framing ('held back') and emphasizes slower-than-expected performance, creating mild concern about near-term growth prospects.”